Besada ML, Romeu CCR, Ramírez TG

Language: Spanish
References: 11
Page: 1-14
PDF size: 976.36 Kb.

ABSTRACT

Introduction: Ciprofloxacin 0.2% otic drop is a β-lactam antibiotic with a broad antibacterial spectrum.
Objective: Validate a method to evaluate the analytical and stability behavior of the ciprofloxacin hydrochloride 0.2 % otic drop.
Methods: The method was based on the separation of the active substance through an Apollo-C18 chromatographic column (5 μm) (250 x 4.6 mm), with ultraviolet detection at 277 nm. A mobile phase composed of a mixture of 870 mL of solution A (phosphoric acid 0.025 mol/L adjusted with triethylamine at pH 3 ± 0.1) and 130 mL of acetonitrile was used, with a flow rate of 2.0 mL/min. The calibration curve was performed in the range of 2.4 to 3.73 10-4 mol/L, (from 80% to 120% of the amount proposed in the technique).
Results: The method was linear, with a correlation coefficient of 0.9998; the statistical test for interception and slope was non-significant. A recovery of 99.9% was obtained in the range of concentrations studied and the Cochran and Student's t tests were not significant. The coefficient of variation in the repeatability study was 0.26% for the 6 replicates tested. In the intermediate precision analyses, the probability values were greater than 0.05, for a 95.0% confidence. In the specificity study, no interference from additional peaks was observed near the retention time of the main product. The analytical method was linear, precise, specific and accurate in the range of concentrations studied.
Conclusions: The validated analytical method for the quantification of the active ingredient ciprofloxacin hydrochloride 0.2 %, allows that for the first time a safe and effective otic medicine appears in the Basic Table of Medicines of Cuba.

REFERENCES

1. Cano I, Sáez O, García A. Otitis Externa. Guía ABE. Madrid: Grupo de PatologíaInfecciosa de AEPap (GPI-AEPAP); 2019 [acceso 22/07/2020]. Disponible en:http://www.guía-abe.es

2. Haddad J, Keesecker S. External otitis. Nelson Textbook of Pediatrics. Chap639. 20 th ed., Elsevier editor. Philadelphia: PA; 2016 p. 12.

3. Luján Roca. Pseudomonas aeruginosa: un adversario peligroso. ActaBioquímica Clínica Latinoamericana.2014 [acceso23/02/2019];48:465-74.Disponible en: http://www.redalyc.org/articulo.oa

4. Colectivo de autores. Cuadro Básico de Medicamentos. La Habana: EditorialCiencias Médicas; 2014. p. 103, 20-22 [acceso 24/01/2020]. Disponible en:http://www.ecimed.sld.cu

5. Colectivo de autores. Estudio de mercado para gotas nasales y gotas óticas. LaHabana: Laboratorios Julio Trigo, AICA; 2014 p. 2, 16, 17-35.

6. CECMED. Regulación 16/2012. Directrices sobre Buenas Prácticas de Fabricaciónde Productos Farmacéuticos. La Habana: Centro Estatal para el Control deMedicamentos, Equipos y Dispositivos Médicos. (CECMED); 2012.

7. The United States Pharmacopeial Convention. Farmacopea de los EstadosUnidos. 42 ed. Estados Unidos de América NF-37. Rockville: Mack Printing; 2019.

8. Quinteros JE, Obando LN. Validación de un método cromatográfico paracuantificación de Ciprofloxacina en tabletas [Tesis de diploma en QuímicaFarmacéutica]: [Ecuador]. Universidad de Guayaquil; 2017 p. 10-17.

9. Centro para el Control Estatal de Medicamentos, Equipos y DispositivosMédicos. Resolución No 40/2014. Anexo No. I de la Regulación No 37/2012,Buenas Prácticas para Laboratorios de Control de Medicamentos. Validación deMétodos Analíticos. La Habana: CECMED; 2014.

10. Colectivo de autores. Técnica de fabricante. Protocolo para la validación deun método analítico por cromatografía líquida de alta resolución para estudiosde estabilidad en el producto ótico Ciprofloxacino 0,2 %. La Habana:Departamento de Investigaciones, AICA PMV-DG2-18-011; 2018.

11. Aksoy B, Küçükgüzel I, Rollas S. Development and Validation of a Stability-Indicating HPLC Method for Determination of Ciprofloxacin Hydrochloride and itsRelated Compounds in Film-Coated Tablets. Cromatog. 2007;66(S2):57-63. DOI:10.1365/s10337-007-0287-6